Rhenman & Partners Asset Management AB lowered its stake in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) by 11.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 377,244 shares of the biopharmaceutical company’s stock after selling 50,398 shares during the period. Rhenman & Partners Asset Management AB owned about 1.01% of Sunesis Pharmaceuticals worth $157,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Shares of NASDAQ SNSS opened at $0.49 on Tuesday. Sunesis Pharmaceuticals, Inc. has a fifty-two week low of $0.20 and a fifty-two week high of $7.69. The stock has a market cap of $18.34 million, a PE ratio of -0.34 and a beta of 2.69.

Several brokerages have recently weighed in on SNSS. Zacks Investment Research lowered Sunesis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 17th. ValuEngine raised Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, HC Wainwright began coverage on Sunesis Pharmaceuticals in a research report on Thursday, December 20th. They set a “neutral” rating and a $0.50 target price on the stock. Five investment analysts have rated the stock with a hold rating, The stock presently has an average rating of “Hold” and a consensus price target of $1.67.

ILLEGAL ACTIVITY NOTICE: “Rhenman & Partners Asset Management AB Has $157,000 Holdings in Sunesis Pharmaceuticals, Inc. (SNSS)” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.watchlistnews.com/rhenman-partners-asset-management-ab-has-157000-holdings-in-sunesis-pharmaceuticals-inc-snss/2815614.html.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Featured Story: Diversification For Individual Investors

Want to see what other hedge funds are holding SNSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS).

Institutional Ownership by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.